OCX
Income statement / Annual
Last year (2024), OncoCyte Corporation's total revenue was $1.88 M,
an increase of 25.15% from the previous year.
In 2024, OncoCyte Corporation's net income was -$60.66 M.
See OncoCyte Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.88 M |
$1.50 M |
$958,000.00 |
$7.73 M |
$1.22 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.14 M
|
$1.09 M
|
$976,000.00
|
$7.54 M
|
$1.86 M
|
$344,000.00
|
$559,000.00
|
$580,000.00
|
$387,000.00
|
$283,000.00
|
| Gross Profit |
$740,000.00
|
$413,000.00
|
-$18,000.00
|
$188,000.00
|
-$639,000.00
|
-$344,000.00
|
-$559,000.00
|
-$580,000.00
|
-$387,000.00
|
-$283,000.00
|
| Gross Profit Ratio |
0.39
|
0.27
|
-0.02
|
0.02
|
-0.53
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.84 M
|
$9.29 M
|
$7.30 M
|
$13.63 M
|
$9.80 M
|
$6.79 M
|
$6.51 M
|
$7.17 M
|
$5.68 M
|
$4.53 M
|
| General & Administrative Expenses |
$10.20 M
|
$10.74 M
|
$21.88 M
|
$22.34 M
|
$16.79 M
|
$13.28 M
|
$7.01 M
|
$9.23 M
|
$5.46 M
|
$4.19 M
|
| Selling & Marketing Expenses |
$3.94 M
|
$2.80 M
|
$1.13 M
|
$11.17 M
|
$6.49 M
|
$2.16 M
|
$1.68 M
|
$2.44 M
|
$1.20 M
|
$324,000.00
|
| Selling, General & Administrative Expenses |
$14.15 M
|
$13.54 M
|
$23.01 M
|
$33.50 M
|
$23.28 M
|
$15.45 M
|
$8.69 M
|
$11.68 M
|
$5.46 M
|
$4.19 M
|
| Other Expenses |
$36.65 M
|
$2.72 M
|
-$67,000.00
|
-$37,000.00
|
$27,000.00
|
-$3,000.00
|
$91,000.00
|
$0.00
|
$0.00
|
$2,000.00
|
| Operating Expenses |
$60.64 M
|
$25.64 M
|
$30.31 M
|
$47.13 M
|
$33.08 M
|
$22.24 M
|
$15.20 M
|
$18.85 M
|
$11.14 M
|
$8.72 M
|
| Cost And Expenses |
$61.78 M
|
$26.64 M
|
$31.29 M
|
$54.67 M
|
$34.94 M
|
$22.24 M
|
$15.20 M
|
$18.85 M
|
$11.14 M
|
$8.72 M
|
| Interest Income |
$0.00
|
$0.00
|
$77,000.00
|
$209,000.00
|
$252,000.00
|
$299,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$84,000.00
|
$52,000.00
|
$77,000.00
|
$209,000.00
|
$252,000.00
|
$299,000.00
|
$216,000.00
|
$217,000.00
|
$28,000.00
|
$19,000.00
|
| Depreciation & Amortization |
$1.56 M
|
$1.68 M
|
$5.22 M
|
$4.21 M
|
$394,000.00
|
$344,000.00
|
$559,000.00
|
$580,000.00
|
$387,000.00
|
$283,000.00
|
| EBITDA |
-$59.02 M |
-$23.12 M |
-$13.32 M |
-$48.46 M |
-$30.54 M |
-$21.90 M |
-$15.20 M |
-$18.27 M |
-$11.14 M |
-$8.44 M |
| EBITDA Ratio |
-31.37
|
-15.38
|
-13.9
|
-6.27
|
-25.12
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-32.45
|
-16.72
|
-18.79
|
-6.08
|
-24.43
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$378,000.00
|
$281,000.00
|
-$615,000.00
|
$854,000.00
|
-$1.48 M
|
-$187,000.00
|
-$552,000.00
|
-$526,000.00
|
-$28,000.00
|
-$17,000.00
|
| Income Before Tax |
-$60.66 M
|
-$24.86 M
|
-$18.61 M
|
-$73.36 M
|
-$31.19 M
|
-$22.43 M
|
-$15.75 M
|
-$19.38 M
|
-$11.17 M
|
-$8.74 M
|
| Income Before Tax Ratio |
-32.25
|
-16.54
|
-19.43
|
-9.49
|
-25.65
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$54.83 M
|
-$9.26 M
|
-$1.25 M
|
-$97,000.00
|
-$336,000.00
|
$217,000.00
|
-$387,000.00
|
-$262,000.00
|
| Net Income |
-$60.66 M
|
-$27.78 M
|
-$73.44 M
|
-$64.10 M
|
-$29.93 M
|
-$22.33 M
|
-$15.75 M
|
-$19.38 M
|
-$11.17 M
|
-$8.74 M
|
| Net Income Ratio |
-32.25
|
-18.48
|
-76.66
|
-8.3
|
-24.62
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.64 |
-3.75 |
-13.26 |
-14.42 |
-9.14 |
-8.71 |
-8.32 |
-12.83 |
-8.42 |
-8.32 |
| EPS Diluted |
-4.64 |
-3.75 |
-13.26 |
-14.42 |
-9.14 |
-8.71 |
-8.32 |
-12.83 |
-8.42 |
-8.32 |
| Weighted Average Shares Out |
$13.07 M
|
$7.65 M
|
$5.54 M
|
$4.45 M
|
$3.27 M
|
$2.56 M
|
$1.89 M
|
$1.51 M
|
$1.33 M
|
$1.05 M
|
| Weighted Average Shares Out Diluted |
$13.07 M
|
$7.65 M
|
$5.54 M
|
$4.45 M
|
$3.27 M
|
$2.56 M
|
$1.89 M
|
$1.51 M
|
$1.33 M
|
$1.05 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
